UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported): September 30, 2004



                               THERMOGENESIS CORP.
             (Exact name of registrant as specified in its charter)



       Delaware                      0-16375                94-3018487
       --------                      -------                ----------
    (State or other                (Commission            (I.R.S. Employer
    jurisdiction of                File Number)          Identification No.)
   incorporation or
     organization)

                                2711 Citrus Road
                        Rancho Cordova, California 95742
                        --------------------------------
    (Address and telephone number of principal executive offices) (Zip Code)

                                 (916) 858-5100
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)
[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))

<PAGE>


Section 2 - Financial Information
---------------------------------

Item 2.02 Results of Operations and Financial Condition.

     ThermoGenesis  Corp.  announced  its  results for the first  quarter  ended
September 30, 2004 on the attached press release.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01 Financial Statements and Exhibits.

         Exhibit No.           Exhibit Description
         -----------           -------------------
         99                    Press release announcing September 30, 2004 first
                               quarter results

<PAGE>


                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                                         THERMOGENESIS CORP.,
                                                         a Delaware Corporation


Dated:  November 9, 2004                                 /s/ Renee Ruecker
                                                         -----------------------
                                                         Renee Ruecker,
                                                         Chief Financial Officer

<PAGE>


                                [GRAPHIC OMITTED]

               THERMOGENESIS CORP. ANNOUNCES FIRST QUARTER RESULTS

     Revenues Increase 12% and Gross Margin Increases 32% over Prior Year -
    Company Makes Key Investments in New Product Development, Clinical Trials
         & Compliance with Section 404 of the Sarbanes-Oxley Act of 2002

Rancho Cordova,  California  (November 9, 2004) - THERMOGENESIS  CORP.  (Nasdaq:
KOOL) today announced results for its first quarter of fiscal 2005. Net revenues
for the quarter ended September 30, 2004 increased 12% to a first quarter record
of $2,397,000,  compared to $2,143,000 for the first quarter of fiscal 2004. The
gross  margin for the first  quarter  increased  32% to  $780,000  or 33% of net
revenues compared to $589,000 or 27% of net revenues for the first quarter ended
September 30, 2003.

The net loss for the quarter ended  September 30, 2004,  was $1,879,000 or $0.04
per basic and diluted common share compared to $1,239,000 or $0.03 per basic and
diluted common share for the first quarter of fiscal 2003. The additional losses
resulted from significantly  increased  investments in research and development,
clinical  and  scientific  affairs  and  compliance  with  Section  404  of  the
Sarbanes-Oxley Act of 2002.

The increased operating expenses were used for the following:

o    Engaged an outside Design and  Development  Engineering  firm (the contract
     should  end by March  2005) to  accelerate  the  development  of the  DACTM
     System, a blood separation  system which supported the FDA 510(k) filing in
     October 2004.

o    Upgraded and expanded our  engineering  capabilities by the addition of our
     new Vice  President of R&D and  increases to our  electrical,  software and
     mechanical  engineering  staff to assure that ongoing  product  development
     efforts meet our 3-year Business Plan milestones.

o    Replacing three (3) clinical sites to complete our Phase III CryoSeal(R) FS
     System clinical trial 150 patient enrollment by March 31, 2005. These sites
     will be operational by the end of November.

o    Completing  the  manufacturing  transfer  to  Kawasumi  Inc.  in  order  to
     accomplish a 30-40% cost  reduction  for the CP-3, a CryoSeal FS processing
     disposable, beginning in the third quarter of fiscal 2005.

o    Expanded our European Sales staff to direct CryoSeal  product sales efforts
     in Europe and the Middle East.

o    Engaged  outside  advisors in connection  with  Sarbanes-Oxley  Section 404
     compliance.

Kevin Simpson, President and Chief Operating Officer stated, "In spite of record
revenues and gross margin for this quarter,  this  quarterly loss is higher than
last year's due to planned  investments  necessary to  accomplish  our strategic
goal of shifting  our revenues  from devices to sales of high margin  single-use
disposables. The market launches of the DAC System and the (Autologous) Thrombin
Processing  Device (TPD) will mark  significant  milestones  on our path towards
that goal in both the Blood Processing and Hospital Wound Care markets."
<PAGE>

The DAC System is an innovative  product which  semi-automates the separation of
whole blood into  components.  The System allows up to six units to be processed
simultaneously.  Included  in  the  Blood  processing  set is a  patented  25 ml
freezing bag compatible for liquid nitrogen storage in the BioArchive(R) System.
The Company has submitted an application pending FDA clearance to market the DAC
System in the United States. The Company  anticipates Beta Site market launch of
the DAC in the third quarter of fiscal 2005.

The  Thrombin  Processing  Device  (TPD) is a  stand-alone  disposable  which is
designed to produce 8.5 ml of autologous  thrombin from  approximately  11 ml of
patient plasma for various applications, including topical hemostasis or release
of growth factors from platelets.  The Company  anticipates market launch of the
TPD in Europe in the third  quarter of fiscal 2005.  The TPD is not available in
the United States.

Company Conference Call
Management will host a conference call today, November 9, 2004 at 11:00am PST to
review the  financial  results  and other  corporate  events,  followed by a Q&A
session. The call can be accessed by dialing:  (800) 860-2442 within the U.S. or
(412) 858-4600  outside the U.S and giving the conference name  "THERMOGENESIS".
Participants  are  asked to call the  assigned  number  approximately  5 minutes
before the  conference  call  begins.  A replay of the  conference  call will be
available  two hours  after the call for the  following  five  business  days by
dialing:  (877) 344-7529 within the U.S. or (412) 317-0088  outside the U.S. and
entering the following account number: 323 and the following passcode: 353367.

About ThermoGenesis Corp.
After  extensive  research,  ThermoGenesis  Corp's newly  introduced  technology
platforms  lead the world in their ability to produce  biological  products from
single units of blood.  Umbilical  cord blood banks are  utilizing the Company's
BioArchive System as a critical enabling  technology for cryogenic  archiving of
their samples of stem cells for transplant, while our CryoSeal FS System is used
to prepare hemostatic and adhesive surgical sealants from patient blood in about
an hour.  ThermoGenesis  Corp. has been a leading  supplier of  state-of-the-art
Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since
1992.

   The statements contained in this release which are not historical facts are
   forward-looking statements that are subject to risks and uncertainties that
   could cause actual results to differ materially from those expressed in the
    forward-looking statements, including, but not limited to, certain delays
      beyond the Company's control with respect to market acceptance of new
   technologies and products, delays in testing and evaluation of products and
    other risks detailed from time to time in the Company's filings with the
                      Securities and Exchange Commission.

                         For More Information, Contact:
                               THERMOGENESIS CORP.
                          Kevin Simpson: (916) 858-5100
                 or visit the web site at www.thermogenesis.com

<PAGE>
                         THERMOGENESIS CORP.
                       Condensed Balance Sheets
                             (Unaudited)

                                               September 30,       June 30,
                                                   2004              2004
                                               -------------      -----------

ASSETS
Current assets:
  Cash and cash equivalents                     $14,961,000       $16,612,000
  Accounts receivable, net                        2,257,000         3,107,000
  Inventory                                       2,890,000         2,470,000
  Other current assets                              557,000           582,000
                                               -------------      -----------

      Total current assets                       20,665,000        22,771,000

Equipment, net                                    1,244,000         1,146,000

Other assets                                        198,000           197,000
                                               ------------       -----------
                                                $22,107,000       $24,114,000
                                               ============       ===========

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
  Accounts payable                               $1,408,000        $1,709,000
  Other current liabilities                         941,000         1,264,000
                                               ------------       -----------

      Total current liabilities                   2,349,000         2,973,000

Long-term liabilities                               125,000           173,000

Stockholders' equity                             19,633,000        20,968,000
                                               ------------       -----------
                                                $22,107,000       $24,114,000
                                               ============       ===========
<PAGE>
                      THERMOGENESIS CORP.
              Condensed Statements of Operations
                          (Unaudited)
<TABLE>
<CAPTION>
<S>                                                                        <C>                      <C>               <C>

                                                                                Three Months Ended
                                                                                    September, 30

                                                                                                                  % Increase
                                                                           2004                    2003             Decrease
                                                                       -----------              ----------------------------
Net revenues                                                            $2,397,000              $2,143,000             12%

Cost of revenues                                                         1,617,000               1,554,000              4%
                                                                       -----------              -----------

    Gross profit                                                           780,000                 589,000             32%
                                                                       -----------              -----------

Expenses:
  Selling, general and administrative                                    1,434,000               1,136,000             26%

  Research and development                                               1,269,000                 699,000             82%
                                                                       -----------              -----------

    Total operating expenses                                             2,703,000               1,835,000             47%
                                                                       -----------              -----------

Interest and other income/expenses                                          44,000                   7,000            529%
                                                                       -----------              -----------
Net loss                                                               ($1,879,000)            ($1,239,000)            52%
                                                                       ===========              ===========

Basic and diluted net loss per common share                                $ (0.04)                $ (0.03)
                                                                       ===========              ===========

Shares used in computing per share data                                 44,923,844              39,460,449
                                                                       ===========              ===========
</TABLE>
[{"type": "8-K", "sequence": "1", "filename": "for110904.txt", "secsgml_size_bytes": 14565}]
{"company-data": {"conformed-name": "THERMOGENESIS CORP", "cik": "0000811212", "assigned-sic": "3821", "irs-number": "943018487", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-82900", "film-number": "041132117"}, "business-address": {"street1": "2711 CITRUS ROAD", "city": "RANCHO CORDOVA", "state": "CA", "zip": "95742", "phone": "9168585100"}, "mail-address": {"street1": "2711 CITRUS ROAD", "city": "RANCHO CORDOVA", "state": "CA", "zip": "95742"}, "former-company": {"former-conformed-name": "INSTA COOL INC OF NORTH AMERICA", "date-changed": "19920703"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported): September 30, 2004

                               THERMOGENESIS CORP.
             (Exact name of registrant as specified in its charter)

       Delaware                      0-16375                94-3018487
       --------                      -------                ----------
    (State or other                (Commission            (I.R.S. Employer
    jurisdiction of                File Number)          Identification No.)
   incorporation or
     organization)

                                2711 Citrus Road
                        Rancho Cordova, California 95742
                        --------------------------------
    (Address and telephone number of principal executive offices) (Zip Code)

                                 (916) 858-5100
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)
[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))
Section 2 - Financial Information
---------------------------------

Item 2.02 Results of Operations and Financial Condition.

     ThermoGenesis  Corp.  announced  its  results for the first  quarter  ended
September 30, 2004 on the attached press release.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01 Financial Statements and Exhibits.

         Exhibit No.           Exhibit Description
         -----------           -------------------
         99                    Press release announcing September 30, 2004 first
                               quarter results
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                         THERMOGENESIS CORP.,
                                                         a Delaware Corporation

Dated:  November 9, 2004                                 /s/ Renee Ruecker
                                                         -----------------------
                                                         Renee Ruecker,
                                                         Chief Financial Officer
[GRAPHIC OMITTED]

               THERMOGENESIS CORP. ANNOUNCES FIRST QUARTER RESULTS

     Revenues Increase 12% and Gross Margin Increases 32% over Prior Year -
    Company Makes Key Investments in New Product Development, Clinical Trials
         & Compliance with Section 404 of the Sarbanes-Oxley Act of 2002

Rancho Cordova,  California  (November 9, 2004) - THERMOGENESIS  CORP.  (Nasdaq:
KOOL) today announced results for its first quarter of fiscal 2005. Net revenues
for the quarter ended September 30, 2004 increased 12% to a first quarter record
of $2,397,000,  compared to $2,143,000 for the first quarter of fiscal 2004. The
gross  margin for the first  quarter  increased  32% to  $780,000  or 33% of net
revenues compared to $589,000 or 27% of net revenues for the first quarter ended
September 30, 2003.

The net loss for the quarter ended  September 30, 2004,  was $1,879,000 or $0.04
per basic and diluted common share compared to $1,239,000 or $0.03 per basic and
diluted common share for the first quarter of fiscal 2003. The additional losses
resulted from significantly  increased  investments in research and development,
clinical  and  scientific  affairs  and  compliance  with  Section  404  of  the
Sarbanes-Oxley Act of 2002.

The increased operating expenses were used for the following:

o    Engaged an outside Design and  Development  Engineering  firm (the contract
     should  end by March  2005) to  accelerate  the  development  of the  DACTM
     System, a blood separation  system which supported the FDA 510(k) filing in
     October 2004.

o    Upgraded and expanded our  engineering  capabilities by the addition of our
     new Vice  President of R&D and  increases to our  electrical,  software and
     mechanical  engineering  staff to assure that ongoing  product  development
     efforts meet our 3-year Business Plan milestones.

o    Replacing three (3) clinical sites to complete our Phase III CryoSeal(R) FS
     System clinical trial 150 patient enrollment by March 31, 2005. These sites
     will be operational by the end of November.

o    Completing  the  manufacturing  transfer  to  Kawasumi  Inc.  in  order  to
     accomplish a 30-40% cost  reduction  for the CP-3, a CryoSeal FS processing
     disposable, beginning in the third quarter of fiscal 2005.

o    Expanded our European Sales staff to direct CryoSeal  product sales efforts
     in Europe and the Middle East.

o    Engaged  outside  advisors in connection  with  Sarbanes-Oxley  Section 404
     compliance.

Kevin Simpson, President and Chief Operating Officer stated, "In spite of record
revenues and gross margin for this quarter,  this  quarterly loss is higher than
last year's due to planned  investments  necessary to  accomplish  our strategic
goal of shifting  our revenues  from devices to sales of high margin  single-use
disposables. The market launches of the DAC System and the (Autologous) Thrombin
Processing  Device (TPD) will mark  significant  milestones  on our path towards
that goal in both the Blood Processing and Hospital Wound Care markets."
The DAC System is an innovative  product which  semi-automates the separation of
whole blood into  components.  The System allows up to six units to be processed
simultaneously.  Included  in  the  Blood  processing  set is a  patented  25 ml
freezing bag compatible for liquid nitrogen storage in the BioArchive(R) System.
The Company has submitted an application pending FDA clearance to market the DAC
System in the United States. The Company  anticipates Beta Site market launch of
the DAC in the third quarter of fiscal 2005.

The  Thrombin  Processing  Device  (TPD) is a  stand-alone  disposable  which is
designed to produce 8.5 ml of autologous  thrombin from  approximately  11 ml of
patient plasma for various applications, including topical hemostasis or release
of growth factors from platelets.  The Company  anticipates market launch of the
TPD in Europe in the third  quarter of fiscal 2005.  The TPD is not available in
the United States.

Company Conference Call
Management will host a conference call today, November 9, 2004 at 11:00am PST to
review the  financial  results  and other  corporate  events,  followed by a Q&A
session. The call can be accessed by dialing:  (800) 860-2442 within the U.S. or
(412) 858-4600  outside the U.S and giving the conference name  "THERMOGENESIS".
Participants  are  asked to call the  assigned  number  approximately  5 minutes
before the  conference  call  begins.  A replay of the  conference  call will be
available  two hours  after the call for the  following  five  business  days by
dialing:  (877) 344-7529 within the U.S. or (412) 317-0088  outside the U.S. and
entering the following account number: 323 and the following passcode: 353367.

About ThermoGenesis Corp.
After  extensive  research,  ThermoGenesis  Corp's newly  introduced  technology
platforms  lead the world in their ability to produce  biological  products from
single units of blood.  Umbilical  cord blood banks are  utilizing the Company's
BioArchive System as a critical enabling  technology for cryogenic  archiving of
their samples of stem cells for transplant, while our CryoSeal FS System is used
to prepare hemostatic and adhesive surgical sealants from patient blood in about
an hour.  ThermoGenesis  Corp. has been a leading  supplier of  state-of-the-art
Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since
1992.

   The statements contained in this release which are not historical facts are
   forward-looking statements that are subject to risks and uncertainties that
   could cause actual results to differ materially from those expressed in the
    forward-looking statements, including, but not limited to, certain delays
      beyond the Company's control with respect to market acceptance of new
   technologies and products, delays in testing and evaluation of products and
    other risks detailed from time to time in the Company's filings with the
                      Securities and Exchange Commission.

                         For More Information, Contact:
                               THERMOGENESIS CORP.
                          Kevin Simpson: (916) 858-5100
                 or visit the web site at www.thermogenesis.com
THERMOGENESIS CORP.
                       Condensed Balance Sheets
                             (Unaudited)

                                               September 30,       June 30,
                                                   2004              2004
                                               -------------      -----------

ASSETS
Current assets:
  Cash and cash equivalents                     $14,961,000       $16,612,000
  Accounts receivable, net                        2,257,000         3,107,000
  Inventory                                       2,890,000         2,470,000
  Other current assets                              557,000           582,000
                                               -------------      -----------

      Total current assets                       20,665,000        22,771,000

Equipment, net                                    1,244,000         1,146,000

Other assets                                        198,000           197,000
                                               ------------       -----------
                                                $22,107,000       $24,114,000
                                               ============       ===========

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
  Accounts payable                               $1,408,000        $1,709,000
  Other current liabilities                         941,000         1,264,000
                                               ------------       -----------

      Total current liabilities                   2,349,000         2,973,000

Long-term liabilities                               125,000           173,000

Stockholders' equity                             19,633,000        20,968,000
                                               ------------       -----------
                                                $22,107,000       $24,114,000
                                               ============       ===========
THERMOGENESIS CORP.
              Condensed Statements of Operations
                          (Unaudited)
Three Months Ended
                                                                                    September, 30

                                                                                                                  % Increase
                                                                           2004                    2003             Decrease
                                                                       -----------              ----------------------------
Net revenues                                                            $2,397,000              $2,143,000             12%

Cost of revenues                                                         1,617,000               1,554,000              4%
                                                                       -----------              -----------

    Gross profit                                                           780,000                 589,000             32%
                                                                       -----------              -----------

Expenses:
  Selling, general and administrative                                    1,434,000               1,136,000             26%

  Research and development                                               1,269,000                 699,000             82%
                                                                       -----------              -----------

    Total operating expenses                                             2,703,000               1,835,000             47%
                                                                       -----------              -----------

Interest and other income/expenses                                          44,000                   7,000            529%
                                                                       -----------              -----------
Net loss                                                               ($1,879,000)            ($1,239,000)            52%
                                                                       ===========              ===========

Basic and diluted net loss per common share                                $ (0.04)                $ (0.03)
                                                                       ===========              ===========

Shares used in computing per share data                                 44,923,844              39,460,449
                                                                       ===========              ===========